teriparatidi

Teriparatide is a recombinant form of human parathyroid hormone consisting of the first 34 amino acids (PTH1-34). It is an anabolic treatment for osteoporosis used in adults at high risk of fracture, including postmenopausal women and men with osteoporosis, and in glucocorticoid-induced osteoporosis in certain settings. By stimulating osteoblast activity more than osteoclast activity when given intermittently, teriparatide increases bone formation, raises bone mineral density, and lowers the risk of vertebral and nonvertebral fractures.

It is administered by daily subcutaneous injection, typically at a dose of 20 micrograms per day. Treatment duration is generally limited to up to 24 months due to safety considerations, including findings from animal studies that raised concerns about osteosarcoma risk. After stopping teriparatide, gains in bone density may wane, and many patients receive an antiresorptive therapy to maintain benefits.

Contraindications and cautions include hypersensitivity to teriparatide or any component, preexisting hypercalcemia, skeletal irradiation, Paget disease of bone, and conditions with an increased baseline risk of osteosarcoma. It is not recommended during pregnancy or lactation. Common adverse effects include nausea, leg cramps, dizziness, injection-site reactions, and transient hypercalcemia or hypercalciuria. Regulatory status and branded formulations vary by country; in many regions it is known by brand names such as Forteo.